Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,706 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial).
Ichida A, Arita J, Hatano E, Eguchi S, Saiura A, Nagano H, Shindoh J, Hashimoto M, Takemura N, Taura K, Sakamoto Y, Takahashi Y, Seyama Y, Sasaki Y, Uemura K, Kokudo N, Hasegawa K. Ichida A, et al. Among authors: hashimoto m. Liver Cancer. 2023 Nov 28;13(3):322-334. doi: 10.1159/000535514. eCollection 2024 Jun. Liver Cancer. 2023. PMID: 38894811 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 36899138
Correction to: Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma.
Kawamura Y, Akuta N, Shindoh J, Matsumura M, Okubo S, Tominaga L, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kozuka T, Kumada H. Kawamura Y, et al. Among authors: hashimoto m. Clin J Gastroenterol. 2023 Oct;16(5):791. doi: 10.1007/s12328-023-01825-7. Clin J Gastroenterol. 2023. PMID: 37392310 No abstract available.
Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy.
Kawamura Y, Akuta N, Shindoh J, Matsumura M, Okubo S, Tominaga L, Yamamoto S, Eriksson Y, Hosaka T, Saitoh S, Sezaki H, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kozuka T, Kumada H. Kawamura Y, et al. Among authors: hashimoto m. Hepatol Res. 2024 Sep 26. doi: 10.1111/hepr.14114. Online ahead of print. Hepatol Res. 2024. PMID: 39324582
4,706 results